Name: 글로벌 시장 동향
SKU: CD7848
Availability: InStock

보고서 요약(국문)

개요
전 세계 바르데-비들 증후군 진단 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 기록하며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
바르데-비들 증후군(BBS)은 여러 신체 기관에 영향을 미치는 유전 질환입니다. 이 질환은 일반적으로 6가지 특징으로 정의됩니다. BBS 환자는 비만, 특히 복부 지방 축적 문제를 겪을 수 있으며, 지적 장애를 동반하는 경우가 많습니다. 또한 신장, 눈, 생식기 기능에 문제가 생기는 경우가 흔합니다. BBS 환자는 손가락이나 발가락이 하나 더 있는 기형으로 태어날 수도 있습니다. BBS의 심각도는 같은 가족 내에서도 개인마다 크게 다릅니다.
BBS는 일반적으로 망막 이영양증으로 인한 시력 문제, 체간 비만, 후축 다지증과 같은 특징을 확인하여 진단합니다. 진단은 임상 소견에 기반하며, 바르데-비들 증후군(BBS)은 전형적인 특징의 발현 양상이 다양하기 때문에 일부 환자는 수년간 명확한 진단을 받지 못할 수 있습니다. 망막 질환 진단에는 안과 전문의와의 상담 및 망막전위도(ERG) 검사를 포함한 검사가 필요할 수 있습니다. ERG는 빛 자극에 대한 망막의 전기적 반응을 측정하는 검사입니다. 특정 BBS1 및 BBS10 유전자 변이가 있는 환자와 같은 경우에는 유전자 검사를 통해 진단을 확정할 수 있습니다. 생화학적 검사 또한 진단에 사용됩니다.
시장 동향: 성장 요인
고급 검사 패널의 도입 증가
고급 검사 패널의 도입 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 특히 차세대 염기서열 분석(NGS) 패널과 같은 고급 검사 패널은 바르데-비들 증후군과 관련된 여러 유전자를 동시에 분석할 수 있도록 합니다. 이러한 접근 방식은 보다 포괄적인 평가를 제공하여 증후군에 기여할 수 있는 더 광범위한 유전적 변이를 식별할 수 있도록 합니다.

예를 들어, Igenomix Bardet-Biedl 증후군 정밀 패널은 섬모병의 감별 진단을 위한 표적 진단 도구로 활용되어 궁극적으로 질병의 관리 및 예후를 개선하는 데 도움이 될 수 있습니다. 이 패널은 차세대 염기서열 분석(NGS)을 사용하여 이 질병과 관련된 유전자를 종합적으로 분석하고 관련 유전자의 전체 범위를 파악합니다.
NGS, PCR 및 기타 첨단 검사 기술은 유전자 검사의 효율성과 비용 효율성을 향상시켰습니다. 이러한 기술은 고처리량 염기서열 분석을 가능하게 하여 단일 검사에서 여러 유전자를 분석할 수 있도록 합니다. 이러한 효율성은 개인과 의료 시스템에 더욱 접근하기 쉽고 비용 효율적인 검사 옵션을 제공할 수 있습니다.
예를 들어, Paragon Genomics CleanPlex Bardet-Biedl 증후군 패널은 Bardet-Biedl 증후군과 관련된 22개 유전자의 생식세포 변이 또는 돌연변이를 검사하기 위해 사전 설계되고 맞춤 제작되는 멀티플렉스 PCR/앰플리콘 기반 표적 염기서열 분석법입니다.

또한, 바르데-비들 증후군의 유병률 증가, 조기 진단 및 치료에 대한 인식 제고, PCR, NGS 등 진단 방법의 발전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.
제약 요인
높은 검사 비용, 바르데-비들 증후군 검사 관련 합병증, 질환의 다양한 원인에 대한 인식 부족 등은 시장 성장을 저해할 것으로 예상되는 요인입니다.
세분화 분석
글로벌 바르데-비들 증후군 진단 시장은 검사 유형, 기술, 최종 사용자 및 지역별로 세분화됩니다.
유전자 검사 부문은 바르데-비들 증후군 진단 시장 점유율의 약 57.5%를 차지했습니다.
유전자 검사 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 바르데-비들 증후군은 주로 유전 질환이며, 진단은 증후군과 관련된 특정 유전자의 돌연변이를 확인하는 데 의존합니다. 유전자 검사는 이러한 돌연변이의 존재를 확인하는 가장 직접적이고 신뢰할 수 있는 방법입니다.

유전자 검사는 이러한 유전자들을 동시에 분석할 수 있게 해줍니다. 임상 평가를 통해 BBS와 관련된 신체적 및 발달적 이상을 확인할 수 있는 반면, 유전자 검사는 원인 유전자의 돌연변이를 식별하여 진단을 확정적으로 내리는 데 도움을 줍니다. 이러한 확진은 정확한 의료 관리와 유전 상담에 필수적입니다.
예를 들어, Invitae의 바르데-비들 증후군 패널은 바르데-비들 증후군(BBS)과 관련된 유전자들을 분석합니다. 이 유전자들은 BBS에 대한 광범위한 분석을 제공하기 위해 현재까지의 연구 결과를 바탕으로 선정되었습니다. 광범위 패널 검사를 통해 단일 임상 징후를 기반으로 여러 잠재적 유전자를 효율적으로 평가할 수 있습니다. 이러한 유전자에 대한 유전자 검사는 진단을 확정하고 치료 및 관리 결정을 내리는 데 도움을 줄 수 있습니다.
지역 분석
북미 지역은 시장 점유율의 약 41.6%를 차지했습니다.
북미 지역은 주요 업체들의 강력한 입지와 이 지역의 조기 진단 수요 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 북미, 특히 미국은 제약 회사와 의료 기기 회사와 같은 주요 업체들이 강력한 입지를 구축하고 있으며, 첨단 기술을 활용하여 더욱 발전된 검사 제품 및 패널 개발에 주력하고 추가 비용을 절감하고 있습니다.
예를 들어, CD Genomics의 맞춤형 바르데-비들 증후군 패널은 Illumina MiSeq/Ion PGM 시스템을 이용한 앰플리콘 시퀀싱을 제공하여 탁월한 커버리지 균일성을 보장함으로써 BBS 관련 유전자의 미세 돌연변이까지 정확하게 검출할 수 있습니다. 맞춤형 바르데-비들 증후군 패널 시퀀싱만이 요구 사항을 충족하고 처리량을 높이며 비용을 절감할 수 있습니다.
또한, 이 지역의 시장 성장을 견인할 것으로 예상되는 요인 중 하나는 질환의 조기 진단에 대한 수요 증가입니다. 이 지역에서 바르데-비들 증후군의 발병률이 증가하고 있으며, 조기 진단은 더 나은 치료에 도움이 됩니다. 예를 들어, 미국 국립보건원(NIH)에 따르면 미국 내 BBS 발병률은 10만 명당 1명으로 추정됩니다. 이는 이 지역에서 더 나은 치료를 위한 BBS 진단에 대한 수요를 증가시키고 있습니다. 경쟁 환경
바르데-비들 증후군 진단 시장의 주요 글로벌 업체로는 Invitae Corporation, Blueprint Genetics Oy, Prevention Genetics, Fulgent Genetics, Paragon Genomics, Inc., Igenomix, CD Genomics, Redcliffe labs, Asper Biogene, Mikrogenlab 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 바르데-비들 증후군 진단 시장에 상당한 영향을 미쳤습니다. 이 팬데믹은 전 세계 여러 산업, 특히 바르데-비들 증후군 진단 시장에 전례 없는 어려움을 초래했습니다. COVID-19 팬데믹과 관련 제한 조치에 대한 관심이 집중되면서 많은 연구 활동이 일시적으로 중단되었기 때문입니다. 또한, 팬데믹은 이러한 진단 제품의 전 세계적인 공급망에 차질을 빚었습니다.

시장 세분화
검사 유형별
• 생화학 검사
• 유전자 검사
• 망막전위검사(ERG)
• 기타
기술별
• 차세대 염기서열 분석(NGS)
• 중합효소 연쇄 반응(PCR)
• 어레이 프라이머 확장(APEX)
• 전체 게놈 염기서열 분석
• 기타
최종 사용자별
• 병원
• 진단 센터
• 가정 간호
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 질병 유형, 치료 유형, 유통 채널 및 지역별 글로벌 바르데-비들 증후군 진단 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 바르데-비들 증후군 진단 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 바르데-비들 증후군 진단 시장 보고서는 약 61개의 표, 61개의 그림, 187페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Bardet-Biedl syndrome diagnostics market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Bardet-Biedl syndrome (BBS) is a genetic condition that impacts multiple body systems. It is classically defined by six features. Patients with BBS can experience problems with obesity, specifically with fat deposition along the abdomen. They often also suffer from intellectual impairments. Commonly, the kidneys, eyes and function of the genitalia will be compromised. People with BBS may also be born with an extra digit on their hands. The severity of BBS varies greatly even among individuals within the same family.
BBS is generally diagnosed based upon the identification of characteristics like visual problems due to retinal dystrophy, truncal obesity and post-axial polydactyly. As diagnosis is based on clinical findings and BBS is associated with variable expression of the classical features, some patients may not have a clear diagnosis for many years. Diagnosis of retinal disease may require consultation with an ophthalmologist and an examination including an electroretinogram (ERG). The ERG is a procedure that measures the electrical response of the retina to light stimulation. Genetic testing may help confirm the diagnosis for some patients like individuals with certain BBS1 and BBS10 gene mutations. Biochemical testing is also used in the diagnosis.
Market Dynamics: Drivers
Increasing adoption of advanced testing panels
The increasing adoption of advanced testing panels is expected to drive the market over the forecast period. Advanced testing panels, particularly next-generation sequencing (NGS) panels, enable the simultaneous analysis of multiple genes associated with Bardet-Biedl Syndrome. This approach provides a more comprehensive assessment, allowing for the identification of a wider range of genetic mutations that may contribute to the syndrome.
For instance, the Igenomix Bardet-Biedl Syndrome Precision Panel can serve as a directed diagnostic tool in making a differential diagnosis of ciliopathies ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes.
NGS, PCR and other advanced testing technologies have improved the efficiency and cost-effectiveness of genetic testing. These technologies allow for high-throughput sequencing, enabling the analysis of multiple genes in a single test. This efficiency can lead to more accessible and cost-effective testing options for individuals and healthcare systems.
For instance, the Paragon Genomics CleanPlex Bardet-Biedl Syndrome Panel is a pre-designed and made-to-order multiplex PCR / amplicon-based targeted sequencing assay for examining the germline variants or mutations across 22 genes associated with Bardet-Biedl Syndrome.
Further, the increasing prevalence of Bardet-Bield syndrome, rising awareness about the early diagnosis for prior treatment and increasing advancements in the diagnosis methods like PCR, NGS and others are the factors expected to drive the market over the forecast period.
Restraints
Factors such as the high cost of the testing, complications associated with the testing of BBS and the lack of awareness about the multiple causes associated with the condition are the factors expected to hamper the market.
Segment Analysis
The global Bardet-Biedl syndrome diagnostics market is segmented based on test type, technology, end-user and region.
The genetic testing segment accounted for approximately 57.5% of the Bardet-Biedl syndrome diagnostics market share
The genetic testing segment is expected to hold the largest market share over the forecast period. Bardet-Biedl syndrome is primarily a genetic disorder and its diagnosis relies on identifying mutations in specific genes associated with the syndrome. Genetic testing is the most direct and reliable way to confirm the presence of these mutations.
Genetic testing allows for the simultaneous analysis of these genes, while clinical evaluation can identify physical and developmental abnormalities associated with BBS, genetic testing helps confirm the diagnosis definitively by identifying mutations in the responsible genes. This confirmation is essential for accurate medical management and genetic counseling.
For instance, the Invitae Bardet-Biedl Syndrome panel analyzes genes that are associated with Bardet-Biedl Syndrome (BBS). These genes were selected based on the available evidence to date to provide a broad analysis for BBS. Broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions.
Geographical Analysis
North America accounted for approximately 41.6% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing demand for early diagnosis of the condition in the region. North America especially the United States is home to the strong presence of major players such as pharmaceutical companies and medical device companies that focus on the development of more advanced testing products and panels by using advanced technologies and by saving additional costs.
For instance, CD Genomics custom Bardet-Biedl syndrome panel offers amplicon sequencing by Illumina MiSeq/Ion PGM system that provides unparalleled coverage uniformity so can accurately detect small mutations in BBS-related genes. Only sequencing the customizable Bardet-Biedl syndrome panel suits the requirements, increases throughput and saves costs.
In addition, the increasing demand for early diagnosis of the condition is also expected to drive the market in the region. There is an increasing prevalence of the Bardet-Biedl syndrome in the region, the early diagnosis helps for better treatment. For instance, according to the National Institute of Health (NIH), in the United States, the prevalence of BBS is estimated at 1 in 100,000. This increases the demand for BBS diagnostics for better treatment in the region.
Competitive Landscape
The major global players in the Bardet-Biedl syndrome diagnostics market include Invitae Corporation, Blueprint Genetics Oy, Prevention Genetics, Fulgent Genetics, Paragon Genomics, Inc., Igenomix, CD Genomics, Redcliffe labs, Asper Biogene and Mikrogenlab among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global Bardet-Biedl syndrome diagnostics market. The pandemic created unprecedented challenges for many industries worldwide, including the global Bardet-Biedl syndrome diagnostics market by temporarily disrupting many research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these testing products globally.
Market Segmentation
By Test Type
• Biochemical Testing
• Genetic Testing
• Electroretinography (ERG)
• Others
By Technology
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Arrayed Primer Extension (APEX)
• Whole Genome Sequencing
• Others
By End-User
• Hospitals
• Diagnostic Centers
• Homecare
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global Bardet-Biedl syndrome diagnostics market segmentation based on disease type, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of Bardet-Biedl syndrome diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Bardet-Biedl syndrome diagnostics market report would provide approximately 61 tables, 61 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Technology
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption of Advanced Testing Panels
4.1.2. Restraints
4.1.2.1. High Cost of Testing
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. SWOT Analysis
5.8. Patent Analysis
5.9. PESTEL Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Test Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
7.1.2. Market Attractiveness Index, By Test Type
7.2. Biochemical Testing*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Genetic Testing
7.4. Electroretinography (ERG)
7.5. Others
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Next-Generation Sequencing (NGS)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Polymerase Chain Reaction (PCR)
8.4. Arrayed Primer Extension (APEX)
8.5. Whole Genome Sequencing
8.6. Others
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Homecare
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Invitae Corporation*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Blueprint Genetics Oy
12.3. PreventionGenetics
12.4. Fulgent Genetics
12.5. Paragon Genomics, Inc.
12.6. Igenomix
12.7. CD Genomics
12.8. Redcliffe labs
12.9. Asper Biogene
12.10. Mikrogenlab
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Invitae Corporation, 4.	Key Developments, Blueprint Genetics Oy, PreventionGenetics, Fulgent Genetics, Paragon Genomics, Inc., Igenomix, CD Genomics, Redcliffe labs, Asper Biogene, Mikrogenlab

표 목록 (Tables)

List of Tables

Table 1 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 7 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2022-2031 (US$ Million)

Table 9 Global Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Bardet-Biedl Syndrome Diagnostics Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 14 North America Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2022-2031 (US$ Million)

Table 15 North America Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Bardet-Biedl Syndrome Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 18 South America Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2022-2031 (US$ Million)

Table 19 South America Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Bardet-Biedl Syndrome Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 22 Europe Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2022-2031 (US$ Million)

Table 23 Europe Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Bardet-Biedl Syndrome Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Value, By Test Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Value, By Technology, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Invitae Corporation: Overview

Table 33 Invitae Corporation: Product Portfolio

Table 34 Invitae Corporation: Key Developments

Table 35 Blueprint Genetics Oy: Overview

Table 36 Blueprint Genetics Oy: Product Portfolio

Table 37 Blueprint Genetics Oy: Key Developments

Table 38 PreventionGenetics: Overview

Table 39 PreventionGenetics: Product Portfolio

Table 40 PreventionGenetics: Key Developments

Table 41 Fulgent Genetics: Overview

Table 42 Fulgent Genetics: Product Portfolio

Table 43 Fulgent Genetics: Key Developments

Table 44 Paragon Genomics, Inc.: Overview

Table 45 Paragon Genomics, Inc.: Product Portfolio

Table 46 Paragon Genomics, Inc.: Key Developments

Table 47 Igenomix: Overview

Table 48 Igenomix: Product Portfolio

Table 49 Igenomix: Key Developments

Table 50 CD Genomics: Overview

Table 51 CD Genomics: Product Portfolio

Table 52 CD Genomics: Key Developments

Table 53 Redcliffe labs: Overview

Table 54 Redcliffe labs: Product Portfolio

Table 55 Redcliffe labs: Key Developments

Table 56 Asper Biogene: Overview

Table 57 Asper Biogene: Product Portfolio

Table 58 Asper Biogene: Key Developments

Table 59 Mikrogenlab: Overview

Table 60 Mikrogenlab: Product Portfolio

Table 61 Mikrogenlab: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 2 Global Bardet-Biedl Syndrome Diagnostics Market Share, By Test Type, 2022-2031 (%)

Figure 3 Global Bardet-Biedl Syndrome Diagnostics Market Share, By Technology, 2022-2031 (%)

Figure 4 Global Bardet-Biedl Syndrome Diagnostics Market Share, By End-User, 2022-2031 (%)

Figure 5 Global Bardet-Biedl Syndrome Diagnostics Market Share, By Region, 2022-2031 (%)

Figure 6 Global Bardet-Biedl Syndrome Diagnostics Market Y-o-Y Growth, By Test Type, 2022-2031 (%)

Figure 7 Biochemical Testing Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 8 Genetic Testing Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 9 Electroretinography (ERG) Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 10 Others Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 11 Global Bardet-Biedl Syndrome Diagnostics Market Y-o-Y Growth, By Technology, 2022-2031 (%)

Figure 12 Next-Generation Sequencing (NGS) Technology in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 13 Polymerase Chain Reaction (PCR) Technology in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 14 Arrayed Primer Extension (APEX) Technology in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 15 Whole Genome Sequencing Technology in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 16 Others Technology in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 17 Global Bardet-Biedl Syndrome Diagnostics Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 18 Hospitals End-User in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 19 Diagnostic Centers End-User in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 20 Homecare End-User in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 21 Others End-User in Global Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 22 Global Bardet-Biedl Syndrome Diagnostics Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 23 North America Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 24 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 25 Europe Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 26 South America Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 27 Middle East and Africa Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 28 North America Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 29 North America Bardet-Biedl Syndrome Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 30 North America Bardet-Biedl Syndrome Diagnostics Market Share, By Technology, 2022 & 2031 (%)

Figure 31 North America Bardet-Biedl Syndrome Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 32 North America Bardet-Biedl Syndrome Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 33 South America Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 34 South America Bardet-Biedl Syndrome Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 35 South America Bardet-Biedl Syndrome Diagnostics Market Share, By Technology, 2022 & 2031 (%)

Figure 36 South America Bardet-Biedl Syndrome Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 37 South America Bardet-Biedl Syndrome Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 38 Europe Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 39 Europe Bardet-Biedl Syndrome Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 40 Europe Bardet-Biedl Syndrome Diagnostics Market Share, By Technology, 2022 & 2031 (%)

Figure 41 Europe Bardet-Biedl Syndrome Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 42 Europe Bardet-Biedl Syndrome Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 43 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 44 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 45 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Share, By Technology, 2022 & 2031 (%)

Figure 46 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 47 Asia-Pacific Bardet-Biedl Syndrome Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 48 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Value, 2022-2031 (US$ Million)

Figure 49 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 50 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Share, By Technology, 2022 & 2031 (%)

Figure 51 Middle East & Africa Bardet-Biedl Syndrome Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 52 Invitae Corporation: Financials

Figure 53 Blueprint Genetics Oy: Financials

Figure 54 PreventionGenetics: Financials

Figure 55 Fulgent Genetics: Financials

Figure 56 Paragon Genomics, Inc.: Financials

Figure 57 Igenomix: Financials

Figure 58 CD Genomics: Financials

Figure 59 Redcliffe labs: Financials

Figure 60 Asper Biogene: Financials

Figure 61 Mikrogenlab: Financials

세계 바르데-비들 증후군 진단 시장 – 2023-2030

Global Bardet-Biedl Syndrome Diagnostics Market - 2023-2030